Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
Javed ButlerStefan D AnkerLars H LundAndrew J S CoatsGerasimos S FilippatosTariq Jamal SiddiqiTim FriedeVincent FabienMikhail KosiborodMarco MetraIleana L PiñaFausto PintoPatrick RossignolPeter van der MeerCecilia BahitJan BelohlavekMichael BöhmJasper J BrugtsJohn G F ClelandJustin EzekowitzAntoni Bayés-GenísIsrael GotsmanAssen GoudevIrakli KhintibidzeJoann LindenfeldRobert J MentzBela MerkelyEliodoro Castro MontesWilfried MullensJose C NicolauAleksandr ParkhomenkoPiotr PonikowskiPetar M SeferovicMichele SenniEvgeny ShlyakhtoAlain Cohen-SolalPeter SzecsödyKlaus JensenFabio DorigottiMatthew R WeirBertram PittPublished in: European heart journal (2022)
Concurrent use of patiromer and high-dose MRAs reduces the risk of recurrent hyperkalemia (ClinicalTrials.gov: NCT03888066).